Key clinical point: Patients with psoriatic arthritis (PsA) who received 100 mg guselkumab once every 4 or 8 weeks (Q4W/Q8W) achieved clinically meaningful improvements through 1 year in several domains of the Patient-Reported Outcomes Measurement Information System.
Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W/Q8W achieved ≥ 5-point improvement in fatigue and sleep disturbance (both P < .05) and in pain interference, physical function, social participation, and pain intensity (all P < .001) compared to patients receiving a placebo. A ≥ 5-point improvement in anxiety ( P < .05) and depression ( P < .01) was achieved by more patients receiving guselkumab Q8W compared to placebo. The improvements were maintained till week 52.
Study details: The findings are from the phase 3 DISCOVER 1 study including 381 patients with active PsA and an inadequate response or tolerance to standard treatments. The patients were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.
Disclosures: This study was funded by Janssen Research & Development, LLC. Seven authors declared being employees of Janssen and stockholders of Johnson and Johnson, the parent company of Janssen. The other authors reported ties with several sources, including Janssen.
Source: Orbai AM et al. Meaningful improvement in general health outcomes with guselkumab treatment for psoriatic arthritis: Patient-reported outcomes measurement information system-29 results from a phase 3 study. Patient. 2022 (Jun 30). Doi: 10.1007/s40271-022-00588-6